DCs can deliver antigenic peptides to CD4+ T lymphocytes via MHC Class II, activating tumor-specific effector T lymphocytes to attack the tumor and shape the host response to malignant cells [16–20, 25–28]. This evidence concerns the gene CD4 and neoplasm.